Wednesday, October 19, 2022 3:11:58 PM
Poor Man -,
I also tend to agree because this will be made out to be just more interim news no matter how much it gets talked about. The first thing new folks see is stock price and OTC. Big red flags for main line investors. The market would have been excited if the journal came out a year ago before SNO. Now, not so much because of the time elapsed and questions as to why such an important breakthrough has not received more main line attention and a quicker pathway forward. They won’t consider why the opposition has been so staunch or that Linda was trying to protect the treatment from being shelved or other. They just want a simple reason to invest in something that others will invest in after them thus driving up the price. That simple answer is manufacturing approval followed by marketing authorization which to me seems to be why the journal article appears to have been linked to manufacturing approval so that the company can then say to the market convincingly that they have applied for marketing authorization and that their application has been accepted or better yet, approved. Anything else is a set up for disappointment so no ASM until they have a good reason to have one. I think they hope to have that good reason “soon” as defined previously by me in response to HappyLibrarian. Best wishes.
I also tend to agree because this will be made out to be just more interim news no matter how much it gets talked about. The first thing new folks see is stock price and OTC. Big red flags for main line investors. The market would have been excited if the journal came out a year ago before SNO. Now, not so much because of the time elapsed and questions as to why such an important breakthrough has not received more main line attention and a quicker pathway forward. They won’t consider why the opposition has been so staunch or that Linda was trying to protect the treatment from being shelved or other. They just want a simple reason to invest in something that others will invest in after them thus driving up the price. That simple answer is manufacturing approval followed by marketing authorization which to me seems to be why the journal article appears to have been linked to manufacturing approval so that the company can then say to the market convincingly that they have applied for marketing authorization and that their application has been accepted or better yet, approved. Anything else is a set up for disappointment so no ASM until they have a good reason to have one. I think they hope to have that good reason “soon” as defined previously by me in response to HappyLibrarian. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
